EGFR and non-small cell lung carcinoma: For example, in advanced EGFR-mutated NSCLC, early changes in the ctDNA value under targeted treatment with osimertinib providing efficacy information, particularly early clearance or decreasing levels of the ctDNA EGFR mutation (also known as molecular response) were associated with subsequent imaging response and with an improvement in response rates (RRs), PFS, and OS [294–296].